Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution

Francesco Pepe & Umberto Malapelle et al.

Recently, precision medicine has drastically modified clinical paradigm for the clinical stratification of high-grade serous ovarian cancer (HGSOC) patients. International societies approved poly (ADP-ribose) polymerase (PARP) inhibitors (PARPIs) to treat platinum-sensitive From May 2023 to Jan 2024 molecular records from 147 HGSOC patients simultaneously tested for Overall, 2 out of 147 (1.3%) cases were morphologically classified as inadequate. Simultaneous HRD testing is a reliable method for the clinical management of HGSOC patients.
Authors
Francesco Pepe, Gianluca Russo, Amedeo Cefaliello, Maria Rosaria Lamia, Roberto Buonaiuto, Giuseppina Crimaldi, Claudia Scimone, Lucia Palumbo, Giuseppina Roscigno, Paola Parente, Maria Chiara De Finis, Fabiola Fiordelisi, Claudia Marchetti, Pierluigi Giampaolino, Carmine De Angelis, Roberto Bianco, Giancarlo Troncone, Umberto Malapelle